Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells is under investigation as an approach to restore productive T cell immunosurveillance in patients with pancreatic ductal adenocarcinoma. Early findings demonstrate safety of this cell-based therapy and the capacity of CAR-...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063135/ |